Biotech News

U.S. Renal Care Presents Analysis of VOICE Trial Demonstrating Favorable Safety Outcomes for Patients Treated with Vadadustat Versus an ESA During a Late-Breaking Session at American Society of Nephrology Kidney Week

Akebia Therapeutics (AKBA)Akebia TherapeuticsClinical readout

Vadadustat demonstrated a clinically meaningful safety outcome benefit in U.S. patients with anemia due to CKD on dialysis utilizing TIW dosing regimen Vadadustat demonstrated a clinically meaningful safety outcome benefit in U.S. patients with anemia due to CKD on dialysis utilizing TIW dosing regimen

Related news

Akebia Therapeutics

Kidney-Disease Company Akebia Therapeutics develops and commercializes medicines for people with kidney disease. Its portfolio combines an anemia franchise with clinical programs for rare and acute renal disorders. Vafseo Vafseo, or vadadustat, is an oral HIF prolyl-hydroxylase inhibitor for anemia due to chronic kidney disease in adults...

Recent company news

Stock data

Close
0.42 USD
Market cap
251.2M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States